# A Placebo Controlled 4 Week Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis (RO-2351-001-EM)

> **NCT00746382** · PHASE2 · WITHDRAWN · sponsor: **AstraZeneca**

## Conditions studied

- Dermatitis

## Interventions

- **DRUG:** Roflumilast cream
- **DRUG:** Placebo cream

## Key facts

- **NCT ID:** NCT00746382
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-11
- **Primary completion:** 2009-06
- **Final completion:** 2009-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study withdrawn due to business decisions. No subjects were treated.
- **Last updated:** 2016-12-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00746382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00746382, "A Placebo Controlled 4 Week Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis (RO-2351-001-EM)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00746382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*